📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-20 12:14
453 analysed today
453
Today
133,342
All-time analysed
40,106
Positive
6,279
Negative
79,144
Neutral
7,745
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
48 announcements match the current filters (relevance ≥ 5).
Q1 FY27 Concall: Cons Revenue ₹99 Cr, Net Loss ₹7.9 Cr as ₹265 Cr Dahej Capex Capitalized
Gem Aromatics reported Q1 FY27 consolidated revenue of ₹99 Cr (up 12.5% YoY from ₹88 Cr), but posted a consolidated net loss of ₹7.9 Cr due to ₹9.1 Cr of depreciation following the capitalization of its Dahej facility. The company has incurred ~₹265 Cr out of its planned ~₹270 Cr capex (representing ~75% of TTM revenue). EBITDA margin stood at 3.3% on a consolidated basis, impacted by operating drag at the new plant and raw material disruptions in the clove vertical caused by Madagascar floods. Management expects commercial supplies from new verticals (cooling agents, Safranal, and phenol derivatives) to scale meaningfully from Q3 and Q4 FY27.
Confidence: HIGH
What changedManagement provided detailed product qualification and revenue ramp-up timelines for new specialty molecules at the Dahej facility following recent asset capitalization.
Why it mattersThe company is transitioning from a mint-dependent business to high-value aroma chemicals and phenol derivatives; near-term earnings remain under pressure from fixed depreciation until new capacity ramps up.
Consolidated Revenue (Q1 FY27): INR 99 croresConsolidated Net Loss (Q1 FY27): INR 7.9 croresDahej Capex Incurred: INR 265 croresCapex vs TTM Revenue: ~75%Depreciation (Q1 FY27): INR 9.1 croresConsolidated EBITDA Margin: 3.3%
📅 Short termProfitability is expected to stay subdued in Q2 FY27 due to fixed operating costs and depreciation, with initial volume traction expected in Q3 FY27.
📈 Long termSuccessful commercialization of non-mint specialty aroma chemicals and phenol derivatives could expand operating margins towards management's medium-term targets as operating leverage kicks in.
⚠ Risk flags
- Raw material supply disruptions and price volatility (e.g., Madagascar clove supply)
- Slow customer qualification cycles delaying Dahej capacity utilization
- Near-term return ratios pressured by high capitalized asset base
Key Highlights
Consolidated revenue stood at ₹99 Cr in Q1 FY27 vs ₹88 Cr in Q1 FY26; standalone revenue reached ₹83 Cr.
Reported consolidated net loss of ₹7.9 Cr, weighed down by ₹9.1 Cr depreciation post capitalization of the Dahej plant.
Total capex of ~₹270 Cr is nearly complete, with ~₹265 Cr already incurred and substantially capitalized.
Commercial production for Safranal and cooling agents (Gemcool 3, 5, 23) has commenced, with meaningful revenue guided from Q3 FY27.
Approved incorporation of a Brazil subsidiary to expand distribution across Latin America.
👀 What to Watch
Track the quarterly commercialization progress and capacity utilization of the Dahej facility over Q2–Q4 FY27, along with gross margin recovery in the clove vertical.
Rs 265 Cr Dahej Capex Capitalized; Q1FY27 Revenue Up 13% but PAT Turns Negative
Gem Aromatics reported a 13% YoY increase in consolidated revenue to Rs 98.9 Cr for Q1FY27, but posted a net loss of Rs 7.9 Cr compared to a profit of Rs 8.0 Cr in the previous year. The bottom line was severely impacted by a 405% surge in depreciation (Rs 9.1 Cr) following the capitalization of the Rs 265 Cr Dahej facility. Gross margins contracted significantly to 16.7% from 29.5% due to higher raw material costs and a seasonally softer product mix. The company is transitioning its portfolio toward higher-value specialty molecules, with commercial production of phenol derivatives expected in Q3FY27.
Confidence: HIGH
What changedThe company has transitioned from a heavy capex phase to an operational phase at its Dahej plant, leading to high non-cash depreciation charges that are currently masking operating performance.
Why it mattersThe Rs 265 Cr investment is massive relative to the company's FY26 revenue of Rs 366.5 Cr; the company's future profitability depends on successfully scaling high-margin specialty products to offset these new fixed costs.
Q1FY27 Consolidated Revenue: Rs 98.9 CrDahej Capex Capitalized: Rs 265 CrCapex vs Market Cap: ~29%Consolidated PAT: Rs -7.9 CrGross Margin: 16.7%Depreciation (Q1FY27): Rs 9.1 Cr
📅 Short termThe stock may face pressure due to the reported net loss and significant margin contraction, as the market digests the impact of high depreciation on the bottom line.
📈 Long termStructural significance is high if the company successfully ramps up the Dahej facility and achieves its target of 16-18% EBITDA margins by shifting away from the volatile mint segment.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High depreciation impacting net profitability
- Raw material price volatility (Clove and Mint)
- Execution risk in ramping up new specialty chemical lines
Key Highlights
Consolidated revenue grew 13% YoY to Rs 98.9 Cr in Q1FY27, despite a seasonally softer quarter.
Capitalized ~Rs 265 Cr for the Dahej facility, representing approximately 29% of the current market capitalization.
Reported a consolidated net loss of Rs 7.9 Cr, primarily due to depreciation jumping to Rs 9.1 Cr from Rs 1.8 Cr YoY.
Gross margins compressed by 1,282 bps YoY to 16.7% due to product mix and higher raw material costs.
Commercial production for Phenol derivatives is targeted for Q3FY27, with revenue contribution expected from Q4FY27.
👀 What to Watch
Monitor the utilization ramp-up at the Dahej facility and the margin trajectory as the product mix shifts toward specialty chemicals; watch for the start of revenue from cooling agents and phenol derivatives in H2FY27.
Gem Aromatics Q1 FY27: Revenue Up 12.8% YoY to ‡98.9 Cr; PAT Turns to ‡7.9 Cr Loss
Gem Aromatics reported a 12.8% YoY increase in consolidated revenue to ‡98.9 cr for Q1 FY27, but faced a sharp decline in profitability. The company posted a consolidated net loss of ‡7.9 cr, down from a profit of ‡8.0 cr in Q1 FY26, primarily due to a 1,282 bps contraction in gross margins. This margin pressure was driven by higher raw material costs (clove floods in Madagascar) and a ‡9.1 cr depreciation charge following the capitalization of the ‡265 cr Dahej facility. Management expects revenue from new high-margin verticals like Phenol derivatives to begin contributing meaningfully from Q4 FY27.
Confidence: HIGH
What changedThe company has transitioned from a profitable entity to a loss-making one at the consolidated level as it begins to absorb the high depreciation and operating costs of its massive ‡265 cr expansion.
Why it mattersThe ‡265 cr capex is significant relative to the company's FY26 revenue of ‡256 cr; the current loss highlights the 'gestation pain' where fixed costs are capitalized before the new capacity generates matching revenue.
Consolidated Revenue (Q1FY27): ‡98.9 crConsolidated PAT (Q1FY27): -‡7.9 crDahej Facility Capex: ‡265 crDepreciation (Q1FY27): ‡9.1 crGross Margin Compression: 1282 bpsCapex vs FY26 Revenue: 103.5%
📅 Short termThe stock may face pressure due to the unexpected consolidated loss and sharp margin erosion, despite the modest YoY revenue growth.
📈 Long termThe structural shift toward higher-margin Phenol and Aroma chemicals is critical for the company to reach its ‡1,050-1,100 cr revenue target by FY28; however, near-term profitability remains at risk from high fixed costs.
⚠ Risk flags
- High fixed-cost burden (depreciation) impacting net profit
- Raw material price volatility in the Clove and Mint segments
- Execution risk in ramping up the new Dahej facility
Key Highlights
Consolidated EBITDA crashed 77.7% YoY to ‡3.3 cr, with margins shrinking from 17.0% to 3.3%.
Depreciation expense surged to ‡9.1 cr following the capitalization of the ‡265 cr Dahej facility.
Gross margins compressed by 1,282 bps YoY to 16.7% due to raw material volatility and product mix.
Secured initial orders for cooling agents (GEM Cool series) with commercial supplies scaling in Q3 FY27.
Approved incorporation of a new wholly-owned subsidiary in Brazil to target the Latin American market.
👀 What to Watch
Watch for the utilization levels of the Dahej facility over the next two quarters; the key trigger will be the commencement of commercial Phenol derivative production in Q3/Q4 FY27 to offset high fixed costs.
Gem Aromatics Q1 Standalone PAT Up 11% to ₹7.25 Cr; Consolidated Swings to ₹7.87 Cr Loss
Gem Aromatics reported a mixed Q1 FY27 performance with standalone revenue growing 8.6% YoY to ₹82.99 cr and standalone PAT rising 11.2% to ₹7.25 cr. However, the consolidated results show a significant net loss of ₹7.87 cr, compared to a profit of ₹7.98 cr in the same quarter last year, indicating a heavy drag from subsidiaries. The company also transitioned its inventory valuation method from Weighted Average to FIFO effective April 1, 2026, which was applied prospectively due to the complexity of its manufacturing processes.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and implemented a significant change in accounting policy for inventory valuation (Weighted Average to FIFO).
Why it mattersThe sharp divergence between standalone and consolidated performance highlights the current financial burden of the company's expansion phase, specifically the new Dahej multi-purpose facility.
Standalone Revenue (Q1 FY27): ₹82.99 crConsolidated Net Loss (Q1 FY27): ₹7.87 crStandalone PAT Growth (YoY): 11.2%Consolidated EPS: ₹(1.56)Standalone Finance Costs: ₹1.33 cr
📅 Short termThe stock may face pressure due to the substantial consolidated loss and the lack of restated comparative figures following the accounting policy change.
📈 Long termThe long-term outlook depends on the company's ability to shift its product mix toward higher-margin Phenol derivatives and achieve its FY28 revenue target of ₹1,050-1,100 cr.
⚠ Risk flags
- Significant consolidated net loss
- Accounting policy change (FIFO) prevents direct historical inventory comparison
- High drag from subsidiary operations
Key Highlights
Standalone revenue from operations increased to ₹82.99 cr from ₹76.40 cr in Q1 FY26.
Consolidated net loss of ₹7.87 cr recorded for the quarter vs a profit of ₹7.98 cr YoY.
Inventory valuation policy changed to FIFO from Weighted Average Cost starting April 1, 2026.
Consolidated EPS dropped to ₹(1.56) from ₹1.70 in the previous year's corresponding quarter.
Standalone finance costs decreased significantly to ₹1.33 cr from ₹2.93 cr YoY.
👀 What to Watch
Investors should monitor the operational ramp-up and path to profitability for the Dahej facility (Krystal Ingredients), which appears to be the primary driver of the consolidated losses.
Gem Aromatics to Expand into Brazil with ₹17 Cr Investment; Appoints New Auditors
Gem Aromatics Limited has approved the incorporation of a wholly-owned subsidiary in Brazil to distribute essential oils and specialty chemicals. The company plans to invest up to ₹2 crore in equity and provide a Standby Letter of Credit (SBLC) of up to ₹15 crore for this international venture. Additionally, the board has appointed M/s. N. L. Bhatia & Associates as Secretarial Auditors for a five-year term and re-appointed M/s. RANK & Associates as Internal Auditors. This expansion signals a strategic push into the South American market to support its global distribution network.
Key Highlights
Approved the incorporation of a Wholly Owned Subsidiary in Brazil for the distribution of essential and specialty chemicals.
Total financial commitment for the Brazil entity includes ₹2 crore equity investment and ₹15 crore SBLC.
M/s. N. L. Bhatia & Associates appointed as Secretarial Auditors for a 5-year term from FY 2026-27 to FY 2030-31.
M/s. RANK & Associates re-appointed as Internal Auditors for the Financial Year 2026-27.
The new Brazil entity will also handle distribution for the company's material subsidiary, Krystal Ingredients Private Limited.
👀 What to Watch
Investors should view the Brazil expansion as a positive growth indicator for the company's export business. Monitor future updates regarding the subsidiary's operational commencement and its contribution to the consolidated top line.
Gem Aromatics to Expand in Brazil with ₹17 Crore Investment; Appoints New Auditors
Gem Aromatics Limited has approved the incorporation of a wholly-owned subsidiary in Brazil to distribute essential oils and specialty chemicals. The company plans a total financial commitment of ₹17 crore, comprising ₹2 crore in equity and a ₹15 crore Standby Letter of Credit (SBLC). On the governance front, the board appointed N. L. Bhatia & Associates as Secretarial Auditors for a five-year term and re-appointed RANK & Associates as Internal Auditors for FY 2026-27. This expansion marks a significant step into the South American market for the company and its subsidiary, Krystal Ingredients.
Key Highlights
Approved the incorporation of a Wholly Owned Subsidiary (WOS) in Brazil for chemical distribution.
Total investment for Brazil expansion includes ₹2 crore equity and ₹15 crore SBLC in one or more tranches.
M/s. N. L. Bhatia & Associates appointed as Secretarial Auditors for a 5-year term (FY 2026-27 to 2030-31).
M/s. RANK & Associates re-appointed as Internal Auditors for the Financial Year 2026-27.
The Brazil entity will support distribution for both Gem Aromatics and its material subsidiary, Krystal Ingredients Private Limited.
👀 What to Watch
Investors should monitor the progress of the Brazil subsidiary's setup as it could significantly boost export revenues. The long-term appointment of secretarial auditors also indicates a focus on stable corporate governance.
Gem Aromatics to Expand into Brazil with ₹17 Crore Investment Commitment
Gem Aromatics Limited has approved the incorporation of a wholly-owned subsidiary (WOS) in Brazil to distribute essential oils and specialty chemicals. The company has committed a total financial outlay of up to ₹17 crore, comprising ₹2 crore in equity and a Standby Letter of Credit (SBLC) of up to ₹15 crore. Additionally, the board has appointed N. L. Bhatia & Associates as Secretarial Auditors for a five-year term and re-appointed RANK & Associates as Internal Auditors for FY 2026-27. This move marks a strategic step toward strengthening the company's international distribution network.
Key Highlights
Approved the incorporation of a 100% Wholly Owned Subsidiary in Brazil for the distribution of essential and specialty chemicals.
Committed an equity investment of up to ₹2,00,00,000 (₹2 Crore) for the new Brazil entity.
Authorized a Standby Letter of Credit (SBLC) of up to ₹15,00,00,000 (₹15 Crore) to support the subsidiary's operations.
Appointed M/s. N. L. Bhatia & Associates as Secretarial Auditors for a 5-year term from FY 2026-27 to FY 2030-31.
Re-appointed M/s. RANK & Associates as Internal Auditors for the Financial Year 2026-27.
👀 What to Watch
Investors should view the Brazil expansion as a positive growth indicator for the company's export business. Monitor future updates regarding the subsidiary's operational commencement and its contribution to the consolidated top-line.
Gem Aromatics MD Yash Parekh Acquires 1.43 Lakh Shares Worth ₹2.18 Crore
Yash Parekh, the Managing Director and CEO of Gem Aromatics Limited, has acquired 1,43,760 equity shares through an open market transaction on June 02, 2026. The total value of the acquisition is approximately ₹2.18 crore. This purchase has increased his personal stake in the company from 9.11% to 9.38%. Significant insider buying by a top executive is typically interpreted as a strong signal of confidence in the company's future performance and valuation.
Key Highlights
MD & CEO Yash Parekh purchased 1,43,760 shares from the open market
Total transaction value stands at approximately ₹2.18 crore
Individual stake increased from 9.11% (47,59,397 shares) to 9.38% (49,03,157 shares)
The transaction was executed on June 02, 2026, and reported on June 04, 2026
👀 What to Watch
This insider buying suggests that the leadership believes the stock is undervalued or expects positive developments. Investors should consider this a positive factor in their fundamental analysis of the company.
Gem Aromatics MD Yash Parekh Acquires 1.43 Lakh Shares Worth ₹2.18 Crore
Yash Parekh, the Managing Director and CEO of Gem Aromatics, has purchased 1,43,760 equity shares of the company through an open market transaction on June 2, 2026. The total value of this acquisition is approximately ₹2.18 crore, representing a significant increase in the promoter's stake. Following this transaction, his total shareholding has risen from 47,59,397 shares to 49,03,157 shares. Such insider buying by top management is generally perceived as a strong signal of confidence in the company's future performance and valuation.
Key Highlights
MD & CEO Yash Parekh purchased 1,43,760 equity shares via open market on June 2, 2026.
The total transaction value is approximately ₹2,18,11,669.70.
Post-acquisition shareholding increased to 49,03,157 shares from 47,59,397 shares.
The trade was executed on the National Stock Exchange (NSE).
👀 What to Watch
Investors should view this significant insider purchase by the CEO as a positive indicator of management's commitment and confidence in the company. It may be worth monitoring the stock for further accumulation or fundamental growth triggers.
Gem Aromatics MD & CEO Yash Parekh Acquires 1.43 Lakh Shares Worth ₹2.18 Crore
Yash Parekh, the Promoter and Managing Director of Gem Aromatics Limited, has increased his stake in the company through an open market purchase on June 02, 2026. He acquired 1,43,760 equity shares, which represents approximately 0.38% of the company's total share capital. The total investment for this transaction was approximately ₹2.18 crores. This move increases his total holding from 11% to 11.38%, signaling strong management confidence in the company's outlook.
Key Highlights
MD & CEO Yash Parekh purchased 1,43,760 equity shares via the open market on June 02, 2026.
The total transaction value was approximately ₹2,18,11,669.70.
Promoter's shareholding increased from 47,59,397 shares (11%) to 49,03,157 shares (11.38%).
The acquisition was disclosed under SEBI (Prohibition of Insider Trading) Regulations, 2015.
👀 What to Watch
Promoter buying in the open market is typically a bullish signal indicating that the leadership believes the stock is undervalued or has strong growth potential. Investors should consider this as a positive factor while performing their fundamental analysis of the company.
Gem Aromatics MD & CEO Yash Parekh Acquires 1.43 Lakh Shares Worth ₹2.18 Crore
Yash Parekh, the Managing Director and CEO of Gem Aromatics Limited, has acquired 1,43,760 equity shares through an open market transaction on June 2, 2026. The total value of the acquisition is approximately ₹2.18 crore, reflecting a significant personal investment by the top executive. Following this purchase, his total shareholding has increased from 4,759,397 to 4,903,157 shares. This move is typically interpreted by the market as a strong signal of management's confidence in the company's long-term value and future prospects.
Key Highlights
MD & CEO Yash Parekh acquired 1,43,760 equity shares via an open market transaction.
The total transaction value is approximately ₹2.18 crore, excluding taxes and brokerage.
The acquisition was completed on June 2, 2026, on the National Stock Exchange (NSE).
Post-acquisition, the promoter's total holding increased to 4,903,157 shares from 4,759,397 shares.
👀 What to Watch
This insider buying by the CEO suggests strong management confidence in the company's valuation. Investors should treat this as a bullish signal while continuing to monitor quarterly financial performance.
Gem Aromatics Q4 FY26: Consolidated Revenue up 40% QoQ, Targets ₹1,100 Cr Revenue by FY28
Gem Aromatics reported a strong sequential recovery in Q4 FY26, with consolidated revenue growing 40% QoQ to ₹110 crore and EBITDA surging 124% to ₹16 crore. The company turned a consolidated profit of ₹1 crore, recovering from a ₹5 crore loss in Q3, despite high depreciation costs. A major milestone was the commencement of production at the Dahej greenfield facility, which has a peak revenue potential of ₹800 crore. Management has provided a long-term guidance of ₹1,100 crore in consolidated turnover with 16-18% EBITDA margins by FY28.
Key Highlights
Consolidated revenue grew 40% QoQ to ₹110 crore with EBITDA margins improving to 14.2%.
Completed ₹260 crore of the planned ₹270 crore capex for the Dahej facility, which is now operational.
The Dahej plant is expected to deliver an asset turn of 3-3.5x, representing ₹800 crore in peak revenue potential.
Management targets consolidated revenue of ₹1,100 crore and EBITDA margins of 16-18% by FY28.
Silvassa plant received the EcoVadis Platinum sustainability rating, placing it in the top tier globally.
👀 What to Watch
Investors should monitor the utilization ramp-up at the new Dahej facility and the stabilization of phenol prices, which are currently impacting production timelines. The long-term revenue target of ₹1,100 crore offers a significant growth trajectory worth watching.
Gem Aromatics Q4FY26: Sequential Recovery with PAT at ₹1 Cr; FY26 Revenue at ₹366.5 Cr
Gem Aromatics reported a consolidated revenue of ₹366.5 Cr for FY26, a decline from ₹504.0 Cr in FY25. While Q4FY26 showed a sequential recovery with revenue rising to ₹110.4 Cr from ₹78.9 Cr in Q3, the consolidated PAT for the full year dropped sharply to ₹1.4 Cr from ₹53.4 Cr. Profitability was significantly impacted by higher depreciation charges following the capitalization of the ₹260 Cr Dahej facility and volatility in petrochemical raw material prices.
Key Highlights
Consolidated Revenue for FY26 stood at ₹366.5 Cr, down from ₹504.0 Cr in the previous fiscal year.
Q4FY26 Consolidated PAT turned positive at ₹1.0 Cr compared to a loss of ₹5.0 Cr in Q3FY26.
Capitalized approximately ₹260 Cr of the planned ₹270 Cr capex for the Dahej facility, leading to increased depreciation costs.
Commenced commercial production of GEM Cool 5 and Safranal at the Dahej facility on February 26, 2026.
The Silvassa plant received the EcoVadis Platinum sustainability rating, placing it in the top global tier for ESG.
👀 What to Watch
Investors should monitor the utilization levels of the newly capitalized Dahej facility and the stabilization of phenol prices, as the company's current bottom line is suppressed by high depreciation and raw material volatility.
Gem Aromatics Q4FY26: Revenue up 40% QoQ to ₹110 Cr; PAT Returns to Black at ₹1 Cr
Gem Aromatics reported a sequential recovery in Q4FY26 with consolidated revenue growing 40% QoQ to ₹110.4 Cr, although YoY performance remains down by 45.4%. The company returned to profitability with a PAT of ₹1 Cr compared to a ₹5 Cr loss in the previous quarter, despite being weighed down by ₹9 Cr in depreciation following the ₹260 Cr Dahej plant capitalization. EBITDA margins improved to 14.2% from 8.9% QoQ, driven by better price realization and a healthier product mix. However, high raw material costs for phenol continue to impact the derivatives segment production timelines.
Key Highlights
Consolidated Q4 revenue grew 39.9% QoQ to ₹110.4 Cr, though it fell 45.4% YoY compared to FY25.
EBITDA margins expanded to 14.2% in Q4 from 8.9% in Q3, aided by operating leverage and better realizations.
Capitalized ₹260 Cr Dahej capex, leading to a significant increase in quarterly depreciation to ₹9 Cr.
Commenced commercial production of GEM Cool 5 and Safranal at the Dahej facility in February 2026.
Phenol derivatives business remains production-ready but impacted by high raw material price volatility.
👀 What to Watch
Investors should monitor the capacity utilization ramp-up at the Dahej facility, as high depreciation will continue to pressure net margins in the short term. The sequential recovery is encouraging, but sustained volume growth is needed to offset the increased fixed cost base from recent expansions.
Gem Aromatics Approves FY26 Results, Appoints New Directors and Cost Auditor
Gem Aromatics Limited held its board meeting on May 21, 2026, to approve the audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The company received a clean audit report with an unmodified opinion from its statutory auditors, Chhajed & Doshi. Significant leadership changes were announced, including the appointment of a new Whole Time Director and an Independent Director. Furthermore, the board approved the appointment of M/s Y.R. Doshi & Associates as the Cost Auditor for the financial year 2026-27.
Key Highlights
Approved audited standalone and consolidated financial results for the full year ended March 31, 2026.
Statutory auditors issued an unmodified opinion on the financial statements, indicating no major accounting discrepancies.
Appointed Mr. Dinesh Vasu Thekkepanakkal as an Additional (Whole Time) Director.
Appointed Mr. Nandan Narula as an Additional (Independent) Director to the Board.
Appointed M/s Y.R. Doshi & Associates as the Cost Auditor for the upcoming FY 2026-27.
👀 What to Watch
Investors should examine the detailed financial performance in the full audit report to evaluate the company's profitability trends. The clean audit opinion and board expansion are positive indicators of corporate governance.
Gem Aromatics Approves FY26 Audited Results; Appoints Whole Time and Independent Directors
Gem Aromatics Limited held a board meeting on May 21, 2026, to approve its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The company announced key leadership changes, including the appointment of Mr. Dinesh Vasu Thekkepanakkal as a Whole Time Director and Mr. Nandan Narula as an Independent Director. The statutory auditors, Chhajed & Doshi, issued an unmodified opinion on the consolidated results, which include subsidiaries Gem Aromatics LLC and Krystal Ingredients Private Limited. Additionally, the board appointed M/s Y.R. Doshi & Associates as the Cost Auditor for the 2026-27 fiscal year.
Key Highlights
Approved audited financial results for the quarter and full year ended March 31, 2026, with an unmodified auditor's opinion.
Appointed Mr. Dinesh Vasu Thekkepanakkal (DIN: 11654033) as Additional (Whole Time) Director.
Appointed Mr. Nandan Narula (DIN: 03466320) as Additional (Independent) Director.
Consolidated results include performance from subsidiaries Gem Aromatics LLC and Krystal Ingredients Private Limited.
Appointed M/s Y.R. Doshi & Associates as Cost Auditor for the upcoming FY 2026-27.
👀 What to Watch
Investors should review the detailed financial statements once released to assess the company's growth and margin performance for FY26. The management appointments appear to be routine governance updates and should be monitored for long-term strategic impact.
Gem Aromatics Approves FY26 Audited Results and Appoints New Directors
Gem Aromatics Limited has approved its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The statutory auditors, Chhajed & Doshi, issued an unmodified opinion, confirming the reliability of the financial statements. To strengthen leadership, the board appointed Mr. Dinesh Vasu Thekkepanakkal as a Whole Time Director and Mr. Nandan Narula as an Independent Director. Additionally, the company has appointed M/s Y.R. Doshi & Associates as Cost Auditors for the 2026-27 financial year.
Key Highlights
Approved audited consolidated and standalone financial results for the full year ended March 31, 2026.
Received an unmodified audit report from Statutory Auditors, indicating clean financial reporting.
Appointed Mr. Dinesh Vasu Thekkepanakkal (DIN: 11654033) as an Additional (Whole Time) Director.
Appointed Mr. Nandan Narula (DIN: 03466320) as an Additional (Independent) Director.
Confirmed M/s Y.R. Doshi & Associates as Cost Auditors for the upcoming FY 2026-27.
👀 What to Watch
Investors should examine the detailed profit and loss figures in the full report to evaluate year-on-year growth. The clean audit opinion and board expansion are positive indicators of corporate governance.
Gem Aromatics Approves FY26 Audited Results and Strengthens Board with New Appointments
Gem Aromatics Limited approved its audited financial results for the quarter and year ended March 31, 2026, during its board meeting on May 21, 2026. The statutory auditors, Chhajed & Doshi, issued an unmodified opinion on the consolidated financial statements, indicating no material discrepancies. The company also announced key leadership changes, including the appointment of a new Whole Time Director and an Independent Director. These moves are aimed at enhancing corporate governance and operational oversight for the upcoming fiscal year.
Key Highlights
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Statutory auditors issued an unmodified opinion, confirming the accuracy and fairness of the financial reports.
Appointed Mr. Dinesh Vasu Thekkepanakkal as an Additional (Whole Time) Director.
Appointed Mr. Nandan Narula as an Additional (Independent) Director to the Board.
Appointed M/s Y.R. Doshi & Associates as the Cost Auditor for the financial year 2026-27.
👀 What to Watch
Investors should review the detailed financial statements to assess the company's revenue and margin performance for FY26. The unmodified audit report and board expansion are positive signs of governance stability.
Gem Aromatics Approves FY26 Audited Results and Strengthens Board with New Appointments
Gem Aromatics Limited has approved its audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026. The statutory auditors issued an unmodified opinion, confirming the reliability of the financial statements. In a move to strengthen leadership, the board appointed Mr. Dinesh Vasu Thekkepanakkal as a Whole Time Director and Mr. Nandan Narula as an Independent Director. Additionally, M/s Y.R. Doshi & Associates was appointed as the Cost Auditor for the 2026-27 fiscal year.
Key Highlights
Approved audited consolidated and standalone financial results for the fiscal year ended March 31, 2026.
Statutory auditors Chhajed & Doshi provided an unmodified audit opinion on the financial statements.
Appointed Mr. Dinesh Vasu Thekkepanakkal as Additional (Whole Time) Director to the board.
Appointed Mr. Nandan Narula as an Additional (Independent) Director to enhance corporate governance.
Designated M/s Y.R. Doshi & Associates as the Cost Auditor for the upcoming FY 2026-27.
👀 What to Watch
Investors should examine the full financial statements to evaluate year-on-year growth in revenue and margins, as the current announcement focuses on governance and compliance. The addition of new directors should be monitored for its impact on future strategic execution.
Promoter Yash Parekh Increases Stake in Gem Aromatics by 0.19% via Open Market Purchase
Mr. Yash Parekh, a member of the promoter group of Gem Aromatics Limited, has increased his stake in the company by acquiring 100,000 equity shares. The transaction was executed through the open market on March 25, 2026, representing a 0.19% stake. This acquisition raises his total holding from 8.92% to 9.11% of the company's total voting capital. Such insider buying is generally perceived as a positive signal regarding the management's confidence in the company's future performance.
Key Highlights
Promoter Yash Parekh acquired 100,000 equity shares (0.19% stake) on March 25, 2026.
The acquisition was conducted via open market transactions.
Total promoter holding for the individual increased from 46,59,397 shares (8.92%) to 47,59,397 shares (9.11%).
The company's total equity base remains at 5,22,37,138 shares with a face value of Rs. 2 each.
👀 What to Watch
Investors should take note of this promoter buying as it indicates internal confidence in the company's valuation. It is advisable to monitor if this trend of stake increase continues across the promoter group.
